Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China
14. juni 2020 oppdatert av: Wen-hong Zhang, Huashan Hospital
The purpose of the study is to collect health-seeking pathways, sociodemographic characteristics and symptoms of 400 newly diagnosed patients with bacteriologically confirmed pulmonary tuberculosis(TB).
Studieoversikt
Status
Fullført
Detaljert beskrivelse
This research is a retrospective, multicenter, case-control study. The purpose of this study is to collect and assess health-seeking pathways, sociodemographic characteristics and symptoms of 400 newly diagnosed patients with bacteriologically confirmed pulmonary tuberculosis(TB).
According to inclusion criteria and exclusion criteria, a total of 400 participants with bacteriologically confirmed TB will be recruited and acquired their health-seeking pathways in different clinical institutions of pulmonary tuberculosis. Totally, 20 TB-designated medical institutions will be conducted in depth, covering the eastern region (7), the central region (8) and the western region (5), each hospital will enroll 20 eligible patients on the basis of convenience.
The cohorts are divided into delayed diagnosis and undelayed diagnosis. The former is defined if The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert. By offline or online interview, we aim to collect basic sociodemographic characteristics, symptoms, health-seeking pathway, including: hospital name, the date of each visit, laboratory tests and radiology evaluation results, diagnosis, treatment, medical and transportation costs. Then list the hospitals of previous consultations and trace their classification through the official website of the Health and Medical Commission. Determine whether these hospital are designated institution based on the CDC's publicity. Consult the laboratory facilities by phone.
The primary objective is to gain the median time of pulmonary tuberculosis diagnosis confirmed and the correlation between the classification of the first-visit-institution and the diagnosis delay of the pulmonary tuberculosis.
The secondary objective is to gain the bacteriology examination coverage rate: anti fast bacteria smear, tuberculosis culture, and GeneXpert; the correlation between the use of fluoroquinolones as anti-infection treatment before tuberculosis diagnosis confirmed and the diagnosis delay of the pulmonary tuberculosis; the sociodemographic characteristics of patients with or without pulmonary tuberculosis diagnosis delay; The rates of onset symptoms and its correlation to diagnosis delayed of pulmonary tuberculosis diagnosis confirmed patients.
Studietype
Observasjonsmessig
Registrering (Faktiske)
400
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Anhui
-
Hefei, Anhui, Kina
- Anhui Province Hospital
-
-
Guangdong
-
Shenzhen, Guangdong, Kina
- The Third People's Hospital of Shenzhen
-
-
Guangxi
-
Beihai, Guangxi, Kina
- Beihai Tuberculosis Hospital
-
-
Guizhou
-
Guiyang, Guizhou, Kina
- Guiyang Public Health Clinical Center
-
-
Hei Longjiang
-
Daqing, Hei Longjiang, Kina
- The 2th Hospital of Daqing
-
-
Henan
-
Zhengzhou, Henan, Kina
- Henan Province Infectious Diseases Hospital
-
-
Hubei
-
Wuhan, Hubei, Kina
- Wuhan Medical Treatment Center
-
-
Hunan
-
Huaihua, Hunan, Kina
- The First People's Hospital of Huaihua
-
-
Jiangsu
-
Taicang, Jiangsu, Kina
- The First People's Hospital of Taicang
-
Xuzhou, Jiangsu, Kina
- Xuzhou Infectious Diseases Hospital Huimei Liu
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina
- Jiangxi Province Chest Hospital
-
-
Jilin
-
Changchun, Jilin, Kina
- Changchun Infectious Diseases Hospital
-
-
Shandong
-
Jinan, Shandong, Kina
- Shandong Province Chest hospital
-
-
Shanghai
-
Shanghai, Shanghai, Kina
- Shanghai Public Health Clinical Center
-
Shanghai, Shanghai, Kina
- 905th Hospital of PLA Navy
-
-
Shanxi
-
Xian, Shanxi, Kina
- Xian Chest Hospital
-
-
Sichuan
-
Luzhou, Sichuan, Kina
- Southwest Medical University Affiliated Hospital
-
-
Yunnan
-
Qiubei, Yunnan, Kina
- Qiubei People's Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina
- Hangzhou Red Cross Hospital
-
Wenzhou, Zhejiang, Kina
- Wenzhou Central Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
15 år og eldre (Barn, Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
In the study, 400 patients with bacteriologically confirmed pulmonary tuberculosis(TB) were chose from 20 hospitals, each hospital select 20 patients according to the eligibility criteria randomly.
These 20 TB-designated medical institutions are covering the eastern region (7), the central region (8) and the western region (5) among China.
Beskrivelse
Inclusion Criteria:
- Bacteriological positive: including positive AFB smear/ culture / molecular test;
- Agree to accept this survey;
Exclusion Criteria:
- HIV antibody positive and AIDS patients;
- Combined with extrapulmonary TB;
- Critically ill patients, and according to the judgment of the research physician, it is impossible to survive for more than 16 weeks;
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
delayed diagnosis
The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days.
Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
|
|
undelayed diagnosis
The length from the first clinical visit date to the diagnosis confirmed date is equal or less than 14 days.
Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The median time of pulmonary tuberculosis diagnosis confirmed
Tidsramme: immediately after asking the medical history and collecting the result of TB diagnosis
|
Time from the date of patients' symptoms onset to the date of pulmonary tuberculosis diagnosis confirmed
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
|
The correlation between the classification of the first-visit-institution and the diagnosis delay of the pulmonary tuberculosis
Tidsramme: immediately after asking the medical history and collecting the result of TB diagnosis
|
We collect the classification and the quality of the first-visit-institution of diagnosis confirmed patients by asking the past medical histories.
According to the evidence of duration from symptoms onset to pulmonary TB diagnosis confirmed, use logistic correlation to find the relation between the classification of the first-visit-institution and the diagnosis delay.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Bacteriology examination coverage rate: anti fast bacteria smear, tuberculosis culture, and GeneXpert.
Tidsramme: immediately after asking the medical history and collecting the result of TB diagnosis
|
According to the patients' health-seeking pathways, calculate the test coverage rates including anti fast bacteria smear, tuberculosis culture, and GeneXpert in different clinical institutions.
The test coverage rates is acquired by recording the laboratory test reports in medical systems or paper version from patients.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
|
The correlation between the use of fluoroquinolones as anti-infection treatment before tuberculosis diagnosis confirmed and the diagnosis delay of the pulmonary tuberculosis
Tidsramme: immediately after asking the medical history and collecting the result of TB diagnosis
|
We collect the fluoroquinolones use evidence of each patients in different clinical institutions by asking the past medical histories and reviewing paper reports from patients as well as medical system.
Then use logistic correlation to find the relation between the fluoroquinolones use history and the diagnosis delay of the pulmonary tuberculosis.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
|
The sociodemographic characteristics of patients with or without pulmonary tuberculosis diagnosis delay.
Tidsramme: immediately after asking the medical history and collecting the result of TB diagnosis
|
Calculating the distribution of patients' sociodemographic characteristics and correlation between results above and pulmonary tuberculosis diagnosis delay.
Patients' sociodemographic characteristics includes: age, sex, marriage status, nation, occupation, education status, annual family income per capita, underlying disease such as diabetes, habits of smoking and habits of drinking alcohol.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
|
The rates of onset symptoms and its correlation to diagnosis delayed of pulmonary tuberculosis diagnosis confirmed patients.
Tidsramme: immediately after asking the medical history and collecting the result of TB diagnosis
|
According to the past medical history of each pulmonary tuberculosis diagnosis confirmed patients, we collect their onset symptoms and calculate the rate respectively.
Then use logistic correlation to find the relation between the onset symptoms and the diagnosis delay of the pulmonary tuberculosis.
|
immediately after asking the medical history and collecting the result of TB diagnosis
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Wenhong Zhang, PHD, Huashan Hospita
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Liu R, Li J, Tan Y, Shang Y, Li Y, Su B, Shu W, Pang Y, Gao M, Ma L. Multicenter evaluation of the acid-fast bacillus smear, mycobacterial culture, Xpert MTB/RIF assay, and adenosine deaminase for the diagnosis of tuberculous peritonitis in China. Int J Infect Dis. 2020 Jan;90:119-124. doi: 10.1016/j.ijid.2019.10.036. Epub 2019 Nov 4.
- Martinez L, Xu L, Chen C, Sekandi JN, Zhu Y, Zhang C, Whalen CC, Zhu L. Delays and Pathways to Final Tuberculosis Diagnosis in Patients from a Referral Hospital in Urban China. Am J Trop Med Hyg. 2017 May;96(5):1060-1065. doi: 10.4269/ajtmh.16-0358. Epub 2017 Feb 13.
- Hogan CA, Puri L, Gore G, Pai M. Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: A systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis. 2016 Dec 13;6:1-7. doi: 10.1016/j.jctube.2016.12.001. eCollection 2017 Jan.
- Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008 Jan 14;8:15. doi: 10.1186/1471-2458-8-15.
- Hanson CL, Osberg M, Brown J, Durham G, Chin DP. Conducting Patient-Pathway Analysis to Inform Programming of Tuberculosis Services: Methods. J Infect Dis. 2017 Nov 6;216(suppl_7):S679-S685. doi: 10.1093/infdis/jix387.
- Hanson C, Osberg M, Brown J, Durham G, Chin DP. Finding the Missing Patients With Tuberculosis: Lessons Learned From Patient-Pathway Analyses in 5 Countries. J Infect Dis. 2017 Nov 6;216(suppl_7):S686-S695. doi: 10.1093/infdis/jix388.
- Farhat MR, Jacobson KR, Franke MF, Kaur D, Murray M, Mitnick CD. Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clin Infect Dis. 2017 Oct 15;65(8):1364-1370. doi: 10.1093/cid/cix556.
- Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan 15;64(2):111-115. doi: 10.1093/cid/ciw778.
- GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. Lancet Infect Dis. 2018 Dec;18(12):1329-1349. doi: 10.1016/S1473-3099(18)30625-X.
- Mijiti P, Yuehua L, Feng X, Milligan PJ, Merle C, Gang W, Nianqiang L, Upur H. Prevalence of pulmonary tuberculosis in western China in 2010-11: a population-based, cross-sectional survey. Lancet Glob Health. 2016 Jul;4(7):e485-94. doi: 10.1016/S2214-109X(16)30074-2. Epub 2016 Jun 6.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
8. september 2019
Primær fullføring (Faktiske)
2. november 2019
Studiet fullført (Faktiske)
10. januar 2020
Datoer for studieregistrering
Først innsendt
14. juni 2020
Først innsendt som oppfylte QC-kriteriene
14. juni 2020
Først lagt ut (Faktiske)
17. juni 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
17. juni 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. juni 2020
Sist bekreftet
1. juni 2020
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- KY-2019TB-20
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
We would like to share the study protocol and statistical analysis plan.
IPD-delingstidsramme
The data is available currently without expiry date.
Tilgangskriterier for IPD-deling
Please contact y_li11@fudan.edu.cn
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .